Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized trial of SHR6508 injection vs cinacalcet in hemodialysis patients with secondary hyperparathyroidism
CTR20223327Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR6508 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Hengrui Therapeutics. Started Dec 2022; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20223327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223327.